Primary data · sourced from public filings·700+ listed companies · India-first·
Open screener
ἀλήθεια · aletheiaAncient Greek for truth — literally “un-forgetting”: the act of revealing reality, not merely stating it
← All posts
Sector Thesis·3 min read·Week 24

Genomics in India: B2B wins, B2C burns cash

B2C genomics in India faces brutal unit economics and 18-24 month sales cycles. B2B plays—diagnostic labs, pharma CROs, agriculture—show 3-4x better margins and 60% faster deals. The path to scale is institutional, not consumer.

ByAmit Tyagi·Fitoor Capital
Aletheia Insights · Weekly

Get 1 unfair insight every week from India's startup ecosystem.

Read by serious founders and investors. No fluff.

Blog Pass

Continue reading with Blog Pass

This piece is part of the Aletheia archive. This week’s drops are free — unlock every sector thesis, deal-flow breakdown and disclosure note with a Blog Pass.

₹999/mo·₹5,000/yrSave 58%
Get Blog Pass →

Amit Tyagi

Founder, AletheiaAI & GP, Fitoor Capital

Veteran of India's startup ecosystem. Writing about fundraising, investor psychology, and what it takes to build fundable startups in India.

Run a fundability check

India's only MRE-backed platform for founders and investors. Analyse your deck, find investors, and validate your raise strategy.

#genomics#b2b-vs-b2c#unit-economics#healthtech

Don’t miss the next one

One insight every week. No fluff.

Aletheia Insights · Weekly

One contrarian insight. Every week. No generic startup advice.

Join founders and investors building with better information.

Genomics in India: B2B wins, B2C burns cash · Aletheia Insights